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Protein kinase C (PKC) is a widely-studied molecular target for the treatment of cancer and other 
diseases. We have approached the issue of modifying PKC function by targeting the C1 domain in 
the regulatory region of the enzyme. Using the X-ray crystal structure of the PKC  C1b domain, 
we have discovered conveniently synthesizable derivatives of dialkyl 5-
(hydroxymethyl)isophthalate that can act as potential C1 domain ligands. Structure-activity studies 
confirmed that the important functional groups predicted by modeling were indispensable for 
binding to the C1 domain and that the modifications of these groups diminished binding. The most 
promising compounds were able to displace radiolabeled phorbol ester ([3H]PDBu) from PKC  
and  at Ki values in the range of 200-900 nM. Furthermore, the active isophthalate derivatives 
could modify PKC activation in living cells either by inducing PKC-dependent ERK 
phosphorylation or by inhibiting phorbol-induced ERK phosphorylation. In conclusion, we report 
here, for the first time, that derivatives of isophthalic acid represent an attractive novel group of C1 
domain ligands that can be used as research tools or further modified for potential drug 
development. 
KEYWORDS: PKC, C1 domain, diacylglycerol, phorbol ester, ERK, isophthalate 
 
INTRODUCTION 
Protein kinase C (PKC) is a family of serine/threonine protein kinases that is involved in the 
regulation of various aspects of cell functions, including cell growth, differentiation, metabolism 
and apoptosis.1 During the past 30 years, it has become clear that PKC isoenzymes play an 
important role in the pathology of several diseases such as cancer, diabetes, stroke, heart failure 
and Alzheimer’s disease.2-8 Therefore, PKC, particularly in the cancer field, has been a subject of 
intensive research and drug development.9 
PKC isoenzymes are activated by lipid-derived second messengers and transmit their signal by 
phosphorylating specific protein substrates. The PKC family consists of ten isoenzymes, which can 
be divided into three subfamilies according to their regulatory domain structure and cofactor 
requirements.10, 11 All PKCs are dependent on anionic phospholipids for activation, with 
phosphatidyl-L-serine being the most important. In addition, classical PKCs (, βI, βII and ) 
require calcium and diacylglycerol (DAG) for activation, whereas novel PKCs (, ε, η and θ) 
require DAG but not calcium. Atypical PKCs  and ι/) require neither calcium nor DAG for 
activation. 
DAG is a second messenger that is generated by the phospholipase C-catalyzed hydrolysis of 
membrane phosphatidylinositol-4,5-bisphosphate (PIP2).12 It selectively interacts with proteins 
containing a C1 domain and induces their translocation to discrete subcellular compartments. For 
some C1 domain containing proteins, such a translocation leads to their activation.13 The C1 
domain is a cysteine-rich sequence that forms a zinc finger structure.10 In the classical and novel 
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PKC isoenzymes, the DAG-sensitive C1 domain is duplicated into a tandem C1 domain consisting 
of C1a and C1b subdomains. Atypical PKCs contain a single C1 domain which is not able to bind 
DAG. Along with the PKC family, there are six additional families of proteins that contain a 
DAG-responsive C1 domain: the protein kinase D, the chimaerins, the guanyl nucleotide-releasing 
proteins RasGRPs, the Unc-13 scaffolding proteins, myotonic dystrophy kinase-related Cdc42-
binding kinases (MRCK) and the DAG kinases β and γ.14, 15 
Since the catalytic domain and, in particular, the ATP binding site of PKC are substantially 
homologous among protein kinases,16 and the number of C1 domain containing proteins is 
considerably smaller than the number of kinases,17 the C1 domain provides an attractive target for 
designing selective PKC modulators (see the review by Blumberg et al.18). While the structure of 
the binding cleft in the C1 domain is highly conserved, selectivity can be achieved by various 
strategies.18 Moreover, several studies have already shown that the regulatory domain may have a 
biological function independent of the catalytic activity of the enzyme,19, 20 thus confirming the 
validity of targeting the regulatory domain as a therapeutic strategy.  
Several classes of high-affinity ligands that target the DAG-binding C1 domain have been 
previously described. Naturally occurring tumor promoters, phorbol esters, were the first ligands 
that were found to bind to the C1 domain of PKC.21 In addition to phorbol esters, naturally 
occurring C1 domain ligands include bryostatins,22 teleocidins,23 aplysiatoxins,24 ingenols25 and 
iridals.26 As most of these C1 domain ligands from natural sources are highly complex in their 
chemical structure, we and other groups have been interested in designing a simple C1 domain 
binding template that is easily amenable to chemical modification. Blumberg and Marquez groups 
have described a large number of conformationally constrained DAG-lactones that act as potent C1 
domain ligands,27, 28 while the Irie group has studied indolactam and benzolactam derivatives as 
selective activators of novel PKC isoenzymes.29, 30 A number of “first generation” C1 domain 
ligands (including calphostin C, bryostatin 1, PEP005 and phorbol esters) are already in clinical 
trials for the treatment of different types of cancer.18 
In this study, we describe the design, synthesis, biological activity, and structure-activity 
relationship of a novel class of C1 domain ligands: small hydrophobic isophthalic acid derivatives. 
At low micromolar concentrations, these isophthalic acid derivatives can compete with phorbol 
ester binding to PKC and modulate ERK1/2 phosphorylation in living cells in a PKC-dependent 
manner. 
 
DESIGN AND SYNTHESIS 
We used the crystal structure of the PKC  C1b domain complexed with phorbol-13-O-acetate31 
as a starting point in the design of novel C1 domain ligands that bind to the same site as phorbol 
esters and DAGs. The X-ray structure of the complex shows that the pivotal polar functional 
groups of the phorbol ester that participate in the recognition of the C1 domain include the 
hydroxyl groups attached to carbons C20 and C4 and the carbonyl group on C3 (Figure 1). 
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According to structure-activity studies,32, 33 the C13 carbonyl group is also important for binding of 
phorbol-13-O-acetate to the C1 domain. We selected diethyl 5-(hydroxymethyl)isophthalate as a 
template for our SAR studies because it is commercially available and easily derivatisable. The C2-
symmetry of diethyl 5-(hydroxymethyl)isophthalate enables two binding orientations, similar to 
DAG-lactones;34 it also contains two of the phorbol ester pharmacophores, namely the hydroxyl 
and the carbonyl functionalities with the same interatomic distance as that found in phorbol.35 
Furthermore, dialkyl 5-(hydroxymethyl)isophthalates contain two carbonyl groups, a prerequisite 
for high affinity binding of DAG-lactones.34 We conducted docking experiments to verify that the 
phorbol-like binding mode, with the correct positioning of the hydrogen bonding network, was 
feasible for dialkyl 5-(hydroxymethyl)isophthalate structures. Indeed, our docked model (I) (Figure 
2) showed that dipentyl 5-(hydroxymethyl)isophthalate was anchored to the bottom of the binding 
site via the same interactions as the phorbol ester, i.e. the ligand’s hydroxyl group is hydrogen 
bonded to the backbone amide proton of Thr 242 and the carbonyls of Thr 242 and Leu 251. The 
model also showed that one of the carbonyl groups of I forms a hydrogen bond with the backbone 
amide proton of Gly 253 in a similar fashion as the C3 carbonyl of phorbol-13-O-acetate. The 
second carbonyl group of I seemed to make no contact with the C1 domain; however, it has been 
proposed that the complex might be stabilized by either a bridging water molecule between this 
carbonyl and the backbone carbonyl of Met 239 or by interactions with charged lipid head 
groups.36 
Hydrophobic interactions are crucial for high affinity binding to the C1 domain. The 
hydrophobic side chains of phorbol esters, DAGs and their analogs are thought to interact with 
either the hydrophobic amino acids (Met 239, Pro 241, Phe 243, Leu 250, Trp 252 and Leu 254) 
surrounding the ligand binding cleft or with the hydrophobic moiety in the lipid bilayer.31, 37 Since 
it is not known how the C1 domain interacts with the membrane, hydrophobic interactions are 
difficult to model. We therefore prepared dialkyl 5-(hydroxymethyl)isophthalate derivates with 
different side chains to analyze their effect on binding affinity and activity. 
We initially prepared simple derivatives of the template (I) that differed in the composition of 
the ester groups in order to investigate the length and shape of the alkyl chains required for 
activity. As starting material for the esters, we chose compounds containing primary and secondary 
alkyl chains as well as compounds containing aromatic groups. (see Table 1 for the structures). To 
investigate the hydrophobicity of the compounds that was necessary for activity, we also prepared 
three additional hydrophilic derivatives. 
The dialkyl 5-(hydroxymethyl)isophthalates (1) were conveniently synthesized in only four steps 
using the commercially available diethyl 5-(hydroxymethyl)isophthalate as the starting material (2) 
(Scheme 1). Protection of the hydroxyl group of 2 as a THP ether (3), which was followed by 
hydrolysis of the ester groups gave the dicarboxylic acid (4). This was subsequently treated with an 
alcohol, CDI, DMAP and DBU, or with an alkyl halide, KI and K2CO3 to give the diesters (5a1-3 
and 5b1-19). Some of the alcohols used in these acylation and substitution reactions were not 
commercially available and were synthesized in our laboratory (see Supporting Information). The 
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hydroxymethyl groups of 5a1-3 and 5b1-19 were deprotected to give the targeted diesters (1a1-3 
and 1b1-19) (Table 1). This procedure was used to prepare all the required diesters with the need 
for only a single chromatographic purification step. In addition to the diesters, the dicarboxylic 
acid (1b20) was prepared by the hydrolysis of (2) (Table 1, see Supporting Information). 
The ester groups of 1a3 and 1b2 were selected to further SAR studies. We focused on the 
hydroxymethyl group of the template (I) and synthesized a group of compounds (15a-e) that 
lacked this group (Scheme 2, Table 2). These were prepared from the corresponding carboxylic 
acids and one unsymmetrical diester (15c) was synthesized among these esters. 
To investigate the significance of having two ester groups in the template molecule (I), we 
prepared three monoesters (22a-c) (Scheme 3 and Table 2). Treatment of 16 with NaOH gave 
monomethyl isophthalate (17). Reduction of the carboxylic acid was performed with borane 
dimethyl sulfide complex (BH3∙SMe2)38 and the resultant alcohol (18) was protected as a THP-
ether (19). Hydrolysis of the methyl ester (19) gave the carboxylic acid (20), which was converted 
to esters (21a-c). Finally, the deprotection of the THP group by PPTS yielded the ester products 
(22a-c). 
 To increase the hydrophilicity of the compounds, we prepared several amide derivatives of 
the diesters (Schemes 4 and 5; Table 2). Synthesis of the 5-(hydroxymethyl)isophthalamides (24a-
b) was initiated by coupling the amines with 4. Subsequent deprotection of the THP groups in 23a-
b produced compounds 24a-b. The reverse diamide (27) was prepared from the 3,5-diaminobenzyl 
alcohol (25) by acylation and the subsequent chemoselective hydrolysis of 26. The second diamide 
was synthesized by catalytic hydrogenation of the nitro groups in 28, followed by acylation of the 
resultant phenylenediamine (29) to give the diamide (30), which was used as a negative control 
compound for binding to the C1 domain of PKC  and . 
In the following set of synthesis reactions, we wanted to investigate the effect of having one ester 
and one amide group in the compound. Synthesis of the 3-(hydroxymethyl)-5-
(alkanoylamino)benzoates (36a-e) was initiated from the commercially available 5-nitroisophthalic 
acid monomethyl ester (31) (Scheme 6 and Table 2). The hydroxymethyl group, which is important 
for binding, was obtained in the first step by chemoselective reduction of the carboxylic acid (31) 
using borane dimethyl sulfide complex. This gave a better yield (84%) than using the borane 
tetrahydrofuran complex (70%).39 The alcohol (32) was protected as a THP ether (33) and the 
subsequent catalytic reduction of the nitro group gave the amine product (34). The subsequent N-
acylation with a set of carboxylic acids yielded the corresponding amides (35a-e) while the final 
deprotection of the THP-groups by PPTS gave the products 36a-e. 
We also prepared one monoester that contained an amide group (39). This synthesis commenced 
with monohydrolysis of the THP-protected diester (3) (Scheme 7) and the subsequent N-acylation 
of 3-(trifluoromethyl)benzylamine with 37 to give 38. Deprotection of the THP ether using PPTS 
and purification by SiO2 column chromatography yielded the amide product (39). 
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Screening and Structure-Activity Analysis for Binding to PKC C1 Domain 
We first screened the synthesized compounds for binding to the C1 domain of recombinant 
human PKC  and  using a filtration method on 96-well plate format.40 We used crude cell 
lysates from baculovirus-infected Sf9 cells as the source for PKC in the assay; the lysate from 
uninfected Sf9 cells did not exhibit any phorbol ester binding (not shown). The compounds were 
used at a concentration range of 0.1 to 20 µM, with the highest concentration being based on the 
estimated maximal solubility in aqueous buffer. The results revealed that the first set of 
compounds with different ester side chains, with the exception of compounds 1b17-1b21 (Table 
1), displaced [20-3H]phorbol-12,13-dibutyrate ([3H]PDBu) from PKC  and  in a concentration-
dependent manner. Compounds 1b17, 1b18 and 1b19 have more hydrophilic side chains and were 
unable to displace [3H]PDBu at the concentration range used. In addition, diethyl 5-
(hydroxymethyl)isophthalate (1b21, Table 1), which contains significantly shorter side chains, and 
5-(hydroxymethyl)isophthalic acid (1b20, Table 1), which lacks the alkyl side chains, were unable 
to bind to the PKC C1 domain under the conditions employed in this study. Compounds 1b10, 
1b11 and 1b13, all with aliphatic carbon side chains and high hydrophobicity, appeared to be the 
most effective in displacing [3H]PDBu from PKC  and . Total binding was the only factor that 
was measured in these initial assays and therefore no binding constants or IC50 values were 
calculated based on these results. 
We next examined the contribution of the hydroxymethyl group and the ester groups to the 
binding affinity of isophthalic acid derivatives. All compounds lacking the hydroxymethyl group 
(replaced with hydrogen, or a methyl, or nitro group) exhibited a significantly diminished binding 
at the concentration range used in this study (Table 2, compounds 15a-e). Additionally, the 
unsymmetrical ligands that lacked one of the ester groups (Table 2, compounds 22a-c) were not 
able to displace [3H]PDBu from PKC (Table 2). Thus, the hydroxymethyl group and both of the 
ester groups are essential for creating sufficient binding affinity to the C1 domain. 
We also investigated the effect of replacing one or both of the ester bonds with amide bonds, 
both to test derivatives with different groups around the aromatic backbone and to increase the 
hydrophilicity of the compounds. The C2-symmetric amides, where both of the ester groups of the 
template I were replaced with amide groups (Table 2, compounds 24a-b, 27 and the negative 
control 30), were unable to bind to PKC with a comparable affinity compared to the original 
compounds. This was true irrespective of the orientation of the amide group (compound 24b 
versus the reverse amide 27). Additionally, most of the monoamide derivatives (Table 2, 
compounds 36a-e and 39) were unable to displace [3H]PDBu from the PKC C1 domain as 
effectively as the original compounds. Only compound 36a, which had a long hydrophobic side 
chain, showed a slight concentration-dependent binding affinity to PKC  and . 
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In summary, our results show that the hydroxymethyl group and the ester groups of the template 
(I) are indispensable for binding to the PKC C1b domain. Modifying these regions of the molecule 
leads to diminished binding. In addition to these functional groups, the amount of hydrophobicity 
of the side chains appears to play an important role in achieving binding affinity in the micromolar 
range. 
 
Binding Affinity Constants of Selected Compounds to Purified PKC  and  
Following the initial screening for binding against PKC  and  we determined the binding 
constants for three of the original diesters (1a3, 1b10 and 1b11). Since the screening data 
suggested that the affinities of most of the ligands were within the same concentration range, we 
did not determine binding constants for all of the ligands. The Kd values determined with 
[3H]PDBu saturation binding and Scatchard analysis to purified commercial recombinant human 
PKC  and  were 1.29 nM and 2.35 nM, respectively (data not shown). We therefore used a 
concentration of 10 nM for the radioligand in the subsequent competition binding experiments. To 
validate the assay we determined the Ki values for 1,2-dioctanoyl-sn-glycerol (DOG) and 
bryostatin 1. DOG inhibited the binding of [3H]PDBu to PKC  with a Ki of 40.1 (± 6.0) nM and 
bryostatin 1 inhibited the binding of [3H]PDBu to PKC  with a Ki of 0.44 (± 0.08) nM (Table 3). 
These values are in accordance with published data.41, 42 The inhibitory binding constants for 
compounds 1a3, 1b10 and 1b11 are shown in Table 3. All three ligands were capable of displacing 
the radioactively labeled PDBu with a comparable submicromolar affinity. The ligands bound to 
both PKC  and  at nearly identical affinities and with no significant selectivity towards either of 
the isoenzymes. In general, the Ki values were somewhat lower for PKC  than for . However, 
compound 1a3 was able to displace a substantially smaller proportion of the radioligand from PKC 
 than from , while 1b10 and 1b11 exhibited similar efficacy towards both isoenzymes (Figure 
3). 
 
The Effect of Isophthalic Acid Derivatives on ERK1/2 Phosphorylation in HeLa Cells 
Since the compounds could compete with PDBu in vitro, we wanted to examine whether they 
were able to penetrate the cell membrane and modulate PKC activity within the cellular 
environment. To investigate this issue, we studied their ability to modulate ERK1/2 
phosphorylation in living cells. ERK1/2 is member of the mitogen activated protein (MAP) kinase 
signaling cascade that controls a broad range of cellular activities.43 It has been shown that 
multiple PKC isoforms can induce ERK1/2 phosphorylation via the Raf-MEK pathway; 
additionally, PMA-induced ERK1/2 phosphorylation is mediated by PKC.44 
Human cervical cancer (HeLa) cells were treated with a 20 M concentration of compounds 1a3, 
1b10 and 1b11 for 1-20 minutes. Compounds 1a3 and 1b10, but not 1b11, induced ERK1/2 
phosphorylation within 3 minutes (Figure 4A). The phosphorylation induced by 1a3 and 1b10 was 
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blocked by pretreatment with the MEK inhibitor U0126 (Figure 4A). The PKC inhibitor Gö6983 
(final conc. 1 µM) inhibited the 1a3 and the 1b10-induced ERK1/2 phosphorylation by 38% ± 7% 
and 36% ± 9% respectively (Figure 4A) as determined by the quantification of western blots from 
3-4 independent experiments. Since 1b11 was able to displace [3H]PDBu from PKC in vitro, but 
could not induce ERK1/2 phosphorylation by itself, we examined whether it could still compete 
with phorbol esters binding to PKC in living cells. HeLa cells were treated with various 
concentrations of 1b11 for 30 minutes before stimulating the cells for 5 minutes with 10 nM PMA. 
PMA alone induced a pronounced phosphorylation of ERK1/2 (Figure 4B). Pretreatment of the 
cells with 1b11 inhibited the PMA-evoked phosphorylation of ERK1/2 in a concentration-
dependent manner (Figure 4B). 
 
DISCUSSION 
Several laboratories have focused their studies on the C1 domain of PKC in order to discover 
PKC-modulating compounds for drug development. Bryostatin 1, a marine-derived compound that 
acts through the C1 domain is currently in phase II clinical trials for the treatment of cancer. 
However, naturally occurring C1 domain ligands are highly complex in their structure. Therefore, 
structural modification with the aim of altering the ligand specificity is difficult.18 DAG-lactones 
and indolactam derivatives, the major groups of synthetic C1 domain ligands, are considerably 
simpler than the natural products,18 however, they are also laborious to synthesize and modify. We 
therefore sought to find simpler template for ligand synthesis, whose structure could be easily 
modified and fine tuned in order to achieve selectivity. 
C2-symmetric diethyl 5-(hydroxymethyl)isophthalate is a commercially available and easily 
derivatisable compound. While being structurally simple, our molecular docking experiments 
showed that its derivative, dipentyl 5-(hydroxymethyl)isophthalate, could bind to the C1 domain of 
PKC in a similar fashion as phorbol esters. The same hydrogen bond interactions that have been 
proposed to occur for other C1 domain ligands (such as phorbol esters35 and DAG-lactones27) 
could be attained with the isophthalate core structure. We synthesized a series of isophthalic acid 
derivatives to confirm their binding to the C1 domain of PKC and to study the impact that different 
side chains had on the binding affinity. Binding studies showed that the compounds were able to 
displace [3H]PDBu from the C1 domains of PKC  and . Modifying the ester side chains had a 
very modest effect on the binding as long as the side chains provided sufficient hydrophobicity, 
which appears to be an important determinant for the binding affinity. The best compounds had 
clogP values higher than 5, whereas analogues with lower clogP values, e.g. the ether analogue 
1b19 of 1b1 (clogP values of 2.35 and 6.33, respectively) did not exhibit high binding affinity. In 
addition, 1b21, which carries short ester groups and has a clogP value of 2.10, could not compete 
with [3H]PDBu for binding of PKC  or  either. The results that highlight the importance of 
hydrophobicity in ligand binding are similar to those reported for other C1 domain ligands35 and 
include the DAG-lactones, which have been shown to have an estimated optimal clogP value 
between 5 and 6.37 However, since the clogP value of PDBu (3.43) is significantly lower, and 
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PDBu has been shown to have a higher affinity to the C1 domain45 than the isophthalate 
derivatives or the DAG-lactones, it might be possible to modify the structure and reduce the 
lipophilicity while increasing the binding affinity. 
We also studied the effects of replacing the structural moieties that, as predicted by the 
pharmacophore model, were required for C1 domain recognition. As expected, the hydroxymethyl 
group and both of the carbonyl groups were important for binding. Surprisingly, the diamide 
derivatives (24a–b and 27) were unable to bind to the PKC C1 domain. This might be due to the 
unfavorable interactions of the two amide protons with the C1 domain. The monoamide 
derivatives 36a-e were also unable to compete with [3H]PDBu for binding to the C1 domain of 
PKC  and  in a similar manner as the corresponding diester analogues. However, the compound 
with the longest and most hydrophobic amide side chain (36a), and therefore the highest clogP 
value (4.84, compared to 0.56-4.26 for 36b-e), exhibited some binding towards PKC. One can 
therefore speculate that both the decreased hydrophobicity and the lack of the other ester group 
contribute to the diminished binding affinity observed with the monoamide derivatives. A 
compound with some similarity to these monoamide derivatives (36a-e) has previously been 
described to inhibit phorbol ester binding to the PKC regulatory domain.46 
Based on the results from screening for [3H]PDBu displacement, we selected compounds 1a3, 
1b10 and 1b11 for further testing. Using the assay developed by the Blumberg group,47 we were 
able to show that the compounds bind to PKC  and  with comparable submicromolar affinities. 
Compounds 1b10 and 1b11 displaced [3H]PDBu from both PKC isoenzymes in a similar manner. 
However, compound 1a3 was able to displace only a small proportion of the radioligand from 
PKC , while exhibiting more efficient displacement of [3H]PDBu from PKC  The differences in 
the spatial geometry of the side chains could be one possible explanation to the observed 
phenomenon. The side chains of 1b10 and 1b11 are aliphatic, and therefore more flexible, than the 
aromatic side chains of 1a3, which are more constrained as a result of the planar conformation of 
the aromatic rings. In addition to the differences in the side chains of the compounds studied, there 
are also differences between individual C1 domains of different PKC isoenzymes. Particularly, 
there is a marked difference in DAG binding between the novel and the classical PKC 
isoenzymes.48 The novel PKC isoenzymes are more sensitive to DAG binding than the classical 
isoenzymes, a phenomenon that appears to be dependent on a single amino acid residue within the 
C1 domain.49 Since the PKC isoforms studied here include both classical PKCs and novel PKCs 
(PKC  and respectively), it is possible that the structures of their binding sites would differ 
sufficiently to contribute to the observed phenomenon. However, differences exist also between 
the affinity of individual C1a and C1b domains of PKC isoenzymes within the subgroups of PKC 
isoenzymes.11 For example, in the case of cPKCs, the C1a domain of PKC  binds DAG with a 
higher affinity than phorbol esters, whereas the PKC C1b domain exhibits higher affinity for 
phorbol esters than for DAG.41 On the other hand, both the C1a and C1b domains of PKC  bind 
DAG and phorbol esters with high affinities.41 Thus, while it is tempting to speculate about the 
basis for this potential selectivity of 1a3 towards classical isoenzymes, making definitive 
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conclusions about the specificity mechanism at this stage may be premature. Further studies with 
different PKC isoenzymes and individual C1 domain constructs are needed to clarify the 
selectivity profile of these compounds. 
The hydrophobicity of the compounds suggests that within a cellular environment the 
compounds could easily diffuse into the cell membranes and reach PKC in a similar manner as that 
of phorbol esters and DAGs. To address both the cell membrane penetration and the modulation of 
PKC activity within cellular environment, we studied the effects of compounds 1a3, 1b10 and 
1b11 on ERK1/2 phosphorylation in HeLa cells. Compounds 1a3 and 1b10 induced ERK1/2 
phosphorylation, which was inhibited by pretreatment with the PKC inhibitor Gö6983 thus 
confirming that the effect was PKC-dependent. Surprisingly, while the structure of 1b11 differs 
from 1b10 by only a single carbon in the ester side chains, 1b11 was unable to induce ERK1/2 
phosphorylation. However, 1b11 inhibited the PMA-induced ERK1/2 phosphorylation, 
demonstrating that it can penetrate the cell membrane and bind to the PKC C1 domain in living 
cells. These results suggest that, under these conditions, compounds 1a3 and 1b10, but not 
compound 1b11, are capable of activating one or more PKC isoforms in HeLa cells. It is possible 
that 1b11 had a weak activating effect on PKC, which was not detected with the ERK 
phosphorylation assay. As a weak activator, 1b11 could still antagonize the effect of a much 
stronger activator (PMA). Such an antagonism has been reported between the PKC activator 
bryostatin 1 and PMA.50 The activation and/or inhibition profiles of these compounds need to be 
studied in more detail. 
Based on the results presented here, we are currently working towards improving the affinity and 
selectivity of the isophthalate derivatives. Since there are additional proteins in cells that contain a 
phorbol-responsive C1 domain, binding of these compounds to non-PKC phorbol ester receptors 
will be studied. Selectivity, while difficult to attain because of the high degree of conservation 
within the binding cleft of the C1 domain, is achievable as demonstrated with the DAG-lactones.28, 
51 Furthermore, preliminary studies have shown that a number of compounds described in this 
report inhibit HeLa cell proliferation (Talman et al. unpublished results); studies to delineate the 
mechanism of those effects are in progress. Additionally, preliminary pharmacokinetic evaluation 
of cell membrane permeability and absorption are currently being carried out on these 
compounds.52 
In conclusion, we describe here a novel group on compounds, dialkyl 5-
(hydroxymethyl)isophthalates, that target the phorbol ester binding site of PKC. The compounds 
displace [3H]PDBu from the C1 domain of PKC  and  in vitro at submicromolar concentrations 
and can regulate PKC-dependent signaling in living cells as shown by the ERK phosphorylation 
studies. The compounds are conveniently and effectively synthesized starting from the 
commercially available diethyl 5-(hydroxymethyl)isophthalate. This makes isophthalic acid 
derivatives an attractive candidate for further SAR studies and for further development as research 
tools or lead compounds in drug development. 
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Materials and General Procedures 
All reagents were commercially available and were acquired from Fluka (Buchs, Switzerland) 
and Sigma-Aldrich (Schnelldorf, Germany). THF and Et2O were distilled from 
sodium/benzophenone ketyl. CHCl3 was distilled from CaH2. Anhydrous DMF was from Fluka 
(Buchs, Switzerland) and was stored over molecular sieves (4 Å) under an inert atmosphere of dry 
argon. All reactions in anhydrous solvents were performed in flame-dried glassware under an inert 
atmosphere of dry argon. The progress of chemical reactions was monitored by thin-layer 
chromatography on silica gel 60-F254 plates acquired from Merck (Darmstadt, Germany) using 
phosphomolybdic acid stain (10% by weight in EtOH) or ninhydrin stain (1.5% by weight in 
EtOH). Flash SiO2 column chromatography was performed with a Merck silica gel 60 (230-400 
mesh) or with a Biotage High-Performance Flash Chromatography Sp4-system (Uppsala, Sweden) 
using a 0.1-mm pathlength flow cell UV-detector/ recorder module (fixed wavelength: 254 nm), 
12-mm or 25-mm flash cartridges, and the indicated mobile phase. 
1H NMR, 13C NMR and DEPT spectra were recorded on a Varian Mercury 300 MHz or a Varian 
Unity 500 MHz spectrometer (Varian, Palo Alto, CA, USA) as solutions in CDCl3, DMSO-d6, 
CD3OD or CD2Cl2. Deuterated solvents were purchased from Aldrich. Chemical shifts (δ) are 
given in parts per million (ppm) relative to the NMR solvent signals (CDCl3 7.26 and 77.21 ppm, 
DMSO-d6 2.50 and 39.52 ppm, CD3OD 3.31 and 49.00 ppm, CD2Cl2 5.32 and 53.80 ppm for 1H 
and 13C NMR, respectively). Multiplicities are indicated by s (singlet), d (doublet), t (triplet), q 
(quartet), quintet (qn) and m (multiplet). The synthesized compounds were analyzed by HPLC-MS. 
HPLC-MS analyses were performed to determine the purity of all tested compounds by a HP1100 
instrument with UV detector (λ 210 nm) and a Perkin Elmer Sciex API3000 triple-quadrupole 
LC/MS/MS mass spectrometer (Applied Biosystems/MDS Sciex, Concord, Canada) with a turbo 
ESI source. Signal separation was carried out by a XTerra MS RP18 column (4.6  30 mm, 2.5 
µm). High resolution mass spectra (HRMS) were run on a Q-TOF Micro (quadrupole time-of-
flight) mass spectrometer (Waters/Micromass, Manchester, UK) with an ESI source in positive ion 
mode. The instrument was calibrated with an internal standard. The elemental analyses were 
conducted by Robertson-Microlit Laboratories (Madison, NJ, USA). Melting points were 
measured with an Electrothermal IA 9100 apparatus. Purity of all tested compounds was >95%. 
LogP values for the compounds were calculated using ChemBioDraw Ultra 11.0 (CambridgeSoft, 
Cambridge, MA, USA). 
[20-3H]Phorbol-12,13-dibutyrate ([3H]PDBu) was custom labeled by Amersham Radiolabeling 
Service (GE Healthcare, Little Chalfont, UK). Unlabeled PDBu, phorbol 12-myristate-13-acetate 
(PMA), phosphatidyl-L-serine (PS) and bovine immunoglobulin G (IgG) were purchased from 
Sigma-Aldrich (Steinheim, Germany). Purified recombinant human PKC  and  were from 
Invitrogen (Carlsbad, CA, USA). Protease inhibitors (Complete Protease Inhibitor Cocktail 
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Tablets) and phosphatase inhibitors (PhosSTOP Phosphatase Inhibitor Cocktail Tablets) were from 
Roche (Mannheim, Germany). Anti-ACTIVE® MAPK polyclonal antibody was from Promega 
(Madison, WI, USA), anti-GAPDH monoclonal antibody and HRP-conjugated goat anti-mouse 
IgG were from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA) and the HRP-conjugated 
goat anti-rabbit IgG was from Bio-Rad Laboratories (Hercules, CA, USA). Precision Plus Protein 
Kaleidoscope Standard ladder (Bio-Rad Laboratories, Hercules, CA, USA) was used as the SDS-
PAGE marker. ECL reagents (SuperSignal-West-Pico-Chemiluminescent-Substrate-Kit) were 
form Pierce (Thermo Fisher Scientific Inc., Rockford, IL, USA). 
Cell culture solutions and reagents were purchased from Invitrogen (Carlsbad, CA, USA) unless 
otherwise stated. Sf9 cells were purchased from Invitrogen. HeLa cells were acquired from 
American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured at 37 °C in a 
humidified, 5% CO2 atmosphere with DMEM (Sigma-Aldrich, Steinheim, Germany) 
supplemented with 10% fetal bovine serum, 100 U/mL penicillin and 100 µg/mL streptomycin. 
 
Molecular Modeling 
Molecular docking modeling was performed using the crystal structure of PKC  C1b domain 
complexed with phorbol-13-O-acetate (Protein Data Bank code: 1ptr).31 First, the phorbol-13-O-
acetate was removed from the structure. The hydrogens, as well as the side chains of Lys 234, Arg 
273 and Glu 274 not visible in the X-ray structure, were subsequently added to the protein and the 
structure was energy minimized in SYBYL 7.0 (Tripos, St Louis, MO) using the TRIPOS force 
field. A hundred iterations using the conjugate gradient method were performed. Superimposition 
of the experimental and minimized structures showed no significant deviations. The minimized 
structure was used for ligand docking. Ligand geometry was optimized using the semiempirical 
AM153 method in Spartan 5.1.3 (Wavefunction Inc., Irvine CA). The docking experiments were 
performed using AUTODOCK3.0.54 Gasteiger-Hückel partial charges were calculated in 
SYBYL7.0 for both protein and ligand. Grid maps with 60×60×60 points and a grid-point spacing 
of 0.375 Å centered in the phorbol binding pocket were calculated. All ligand torsion angles were 
considered as flexible. Fifty separate docking simulations were performed using the Lamarckian 
genetic algorithm. A validation of the docking protocol was performed using phorbol-13-O-acetate 
as ligand. The X-ray structure was well reproduced as described previously.37 
 
Synthesis 
Procedures for the synthesis and analysis of the remaining compounds are available in the 
Supporting Information. 
Diethyl 5-(tetrahydropyran-2-yloxymethyl)isophthalate (3). A mixture of diethyl (5-
hydroxymethyl)isophthalate (2) (5.72 g, 22.7 mmol), 3,4-dihydro-2H-pyran (5.54 mL, 61.3 mmol, 
2.7 equiv.), pyridinium toluene-p-sulfonate (285 mg, 1.14 mmol, 0.05 equiv.) and 1,2-
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dichloroethane (50 mL) was stirred at room temperature for 6 h. The reaction mixture was 
quenched by the addition of cold water (50 mL), extracted with DCM (50 mL), and washed with a 
saturated solution of NaHCO3 (3×20 mL) and brine (3×20 mL). The organic phases were dried 
over Na2SO4, filtered and evaporated in vacuo to give 3 as a pale yellow oil (7.41 g, 97% yield). 
This oil was used without further purification and full product analysis was carried out for the 
following product. 
5-(Tetrahydropyran-2-yloxymethyl)isophthalic acid (4). A mixture of 3 (3.46 g, 10.3 mmol), 
a 10% solution of KOH (46.2 mL, 82.4 mmol, 8 equiv.) and MeOH (50 mL) was refluxed for 1 h. 
The solvents were evaporated in vacuo and pH was adjusted with a 25% solution of KHSO4 to 4.0. 
The white precipitate was filtered, washed with water (10 mL), dissolved into a solution of EtOAc 
and THF (1:1, 3×50 mL), dried over Na2SO4, filtered and evaporated in vacuo to give 4 as a white 
solid (2.45 g, 85% yield). This solid was used without further purification. 1H NMR (300 MHz, 
DMSO-d6): δppm 13.3 (bs, 2H), 8.39 (t, 1H, J 1.5 Hz), 8.13 (d, 2H, J 1.5 Hz), 4.80 (d, 1H, J 12.6 
Hz), 4.72 (t, 1H, J 3.0 Hz), 4.59 (d, 1H, J 12.6 Hz), 3.82-3.75 (m, 1H), 3.52-3.45 (m, 1H), 1.80-
1.62 (m, 2H), 1.58-1.48 (m, 4H); 13C NMR (75.4 MHz, DMSO-d6): δppm 166.5, 139.8, 132.1, 
131.3, 129.0, 97.7, 67.3, 61.4, 30.1, 25.0, 19.1. 
Bis(3-trifluoromethylbenzyl) 5-(tetrahydropyran-2-yloxymethyl)isophthalate (5a3). A 
mixture of 4 (1.00 g, 3.57 mmol), 3-(trifluoromethyl)benzyl chloride (2.08 mL, 10.7 mmol, 3 
equiv.), K2CO3 (2.47 g, 17.8 mmol, 5 equiv.) and KI (650 mg, 3.92 mmol, 1.1 equiv.) in dry DMF 
(18 mL) was heated at 80 C for 150 min. The reaction mixture was cooled to rt, quenched by the 
addition of an ice water mixture (20 mL), extracted with EtOAc (3×20 mL), dried over Na2SO4, 
filtered and evaporated in vacuo to give 5a3 as a brown oil. This and the following crude diesters 
(5b10-11) were used in the subsequent deprotection step without further purification and full 
product analysis was carried out for the products 1a3 and 1b10-11. 
Bis(1-ethylbutyl) 5-(tetrahydropyran-2-yloxymethyl)isophthalate (5b10). A mixture of 4 
(250 mg, 0.89 mmol) and 1,1-carbonyldiimidazole (318 mg, 1.96 mmol, 2.2 equiv.) in dry DMF (1 
mL) was stirred at room temperature for 1 h. 3-Hexanol (330 L, 2.68 mmol, 3 equiv.), 4-
(dimethylamino)pyridine (11 mg, 0.09 mmol, 0.1 equiv.) and 1,8-diazabicyclo[5.4.0]undec-7-ene 
(332 μL, 1.78 mmol, 2 equiv.) were added to the reaction mixture that was stirred at 40 C for 43 
h. The reaction was quenched with ice water (10 mL) and extracted with EtOAc (3×20 mL). The 
combined organic phases were washed with a saturated solution of NaHCO3 (2×20 mL), brine (20 
mL), dried over Na2SO4, filtered and evaporated in vacuo to give the crude 5b10, which was 
obtained as a yellow oil after work up. 
Bis(1-ethylpentyl) 5-(tetrahydropyran-2-yloxymethyl)isophthalate (5b11). A mixture of 4 
(250 mg, 0.89 mmol) and 1,1-carbonyldiimidazole (318 mg, 1.96 mmol, 2.2 equiv.) in dry DMF (1 
mL) was stirred at room temperature for 1 h. 3-Heptanol (380 L, 2.68 mmol, 3 equiv.), 4-
(dimethylamino)pyridine (11 mg, 0.09 mmol, 0.1 equiv.) and 1,8-diazabicyclo[5.4.0]undec-7-ene 
(332 μL, 1.78 mmol, 2 equiv.) were added to the reaction mixture and was stirred at 40 C for 43 
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h. The reaction was quenched with ice water (10 mL) and extracted with EtOAc (3×20 mL). The 
combined organic phases were washed with a saturated solution of NaHCO3 (2×20 mL), brine (20 
mL), dried over Na2SO4, filtered and evaporated in vacuo to give the crude 5b11, which was 
obtained as a yellow oil after work up. 
A general procedure III, deprotection of the THP ethers: Bis(3-trifluoromethylbenzyl) 5-
(hydroxymethyl)isophthalate (1a3). A mixture of the crude 5a3 and Dowex 50W×8 (750 mg) in 
MeOH (8 mL) was stirred at 40 C for 23 h. The crude product was purified with flash SiO2 
column chromatography (n-hexane/EtOAc, 12:1 → 1:2) to give 1a3 as a white solid (765 mg, 42% 
yield for two reaction steps). Rf 0.21 (n-hexane/EtOAc, 2:1). mp 90.1-90.6 °C; 1H NMR (300 
MHz, CDCl3): δppm 8.67 (s, 1H), 8.28 (s, 2H), 7.71 (s, 2H), 7.66–7.62 (m, 4H), 7.53 (t, 2H, J 7.8 
Hz), 5.44 (s, 4H), 4.83 (d, 2H, J 5.5 Hz), 1.87 (t, 1H, J 5.5 Hz); 13C NMR (75.4 MHz, CDCl3): 
δppm 165.5, 142.3, 136.8, 132.6, 131.9, 131.3 (q, J 32.5 Hz), 130.8, 130.3, 129.4, 125.5 (q, J 3.74 
Hz), 125.3 (q, J 3.85 Hz), 124.1 (q, J 273 Hz), 66.5, 64.3; Anal. (C25H18F6O5) C, H: calcd, 3.54; 
found, 3.31. 
Bis(1-ethylbutyl) 5-(hydroxymethyl)isophthalate (1b10). The general procedure III was 
followed except that 5b10 was used and the reaction mixture was stirred for 20 h. The crude 
product was purified with flash SiO2 column chromatography (n-hexane/EtOAc, 2:1) to give 1b10 
as a colorless oil (199 mg, 61% yield for two reaction steps). Rf 0.47 (n-hexane/EtOAc, 2:1). 1H 
NMR (300 MHz, CDCl3): δppm 8.62 (app. t, 1H, J 1.5 Hz), 8.22 (app. d, 2H, J 1.2 Hz), 5.16-5.08 
(m, 2H), 4.82 (s, 2H), 1.86 (bs, 1H), 1.76-1.56 (m, 8H), 1.48–1.30 (m, 4H), 0.98-0.91 (m, 12H); 
13C NMR (75.4 MHz, CDCl3): δppm 165.8, 141.8, 132.0, 131.8, 130.1, 76.8, 64.6, 36.1, 27.3, 18.9, 
14.2, 9.9; DEPT 132.0 (CH), 130.1 (CH), 76.8 (CH), 64.6 (CH2), 36.1 (CH2), 27.3 (CH2), 18.9 
(CH2), 14.2 (CH3), 9.9 (CH3). HRMS-ESI (m/z): [M+HCOO-]- calcd 409.2226; found 409.2238. 
Bis(1-ethylpentyl) 5-(hydroxymethyl)isophthalate (1b11). The general procedure III was 
followed except that 5b11 was used and the reaction mixture was stirred for 20 h. The crude 
product was purified with flash SiO2 column chromatography (n-hexane/EtOAc, 2:1) to give 1b11 
as a colorless oil (213 mg, 61% yield for two reaction steps). Rf 0.41 (n-hexane/EtOAc, 4:1). 1H 
NMR (300 MHz, CDCl3): δppm 8.61 (app. t, 1H), 8.23 (m, 2H), 5.10 (qn, 2H, CH, J 6.0Hz), 4.82 
(s, 2H), 1.95 (bs, 1H), 1.76–1.65 (m, 8H), 1.38–1.30 (m, 8H), 0.95 (t, 6H, J 7.5Hz), 0.89 (t, 6H, J 
7.2Hz); 13C NMR (75.4 MHz, CDCl3): δppm 165.8, 141.8, 132.1, 131.8, 130.1, 77.1, 64.6, 33.6, 
27.7, 27.3, 22.8, 14.2, 9.9. HRMS-ESI (m/z): [M+HCOO-]- calcd 437.2539; found 437.2512. 
 
Cloning and Production of Recombinant Human PKC  and  in Insect Cells 
The cloning of human recombinant PKC  and  and their expression in baculovirus-infected 
Sf9 insect cells was performed as described previously.55, 56 For production of the PKC proteins, 
Sf9 cells were infected with an optimized amount of the recombinant baculovirus, harvested 2 days 
post-infection and washed with PBS. The resultant cell pellets were subsequently frozen. Crude 
cell lysates were prepared by suspending the cells in buffer containing 25 mM Tris-HCl (pH 7.5), 
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0.5 mM EGTA, 0.1% Triton-X 100 and protease inhibitors according to the manufacturer’s 
instructions (see Materials and General Procedures). After a 30-minute incubation on ice, the 
lysate was centrifuged at 16000g for 15 minutes at 4 °C and the supernatant was collected. The 
protein content was determined according to Bradford57 and the supernatant was used for 
[3H]PDBu binding experiments.  
 
[3H]PDBu Binding Assay for Initial Screening of Binding Affinity 
The ability of the compounds to compete with radioactively labeled phorbol ester [3H]PDBu in 
binding to the regulatory domain of PKC  and  was determined according to Gopalakrishna et 
al.40 Twenty micrograms of protein/well from the supernatant (see Cloning and Production of 
Recombinant Human PKC  and  in Insect Cells) was incubated with different concentrations of 
each compound and [3H]PDBu for 10 minutes at room temperature in a 96-well Durapore filter 
plate (Millipore, Cat No MSHVN4B50, Bedford, MA, USA) in a total volume of 125 µL. The 
final concentrations in the assay were as follows: 20 mM Tris-HCl (pH 7.5), 40 µM CaCl2, 10 mM 
MgCl2, 400 µg/mL bovine IgG, 25 nM [3H]PDBu and 0.1 mg/mL phosphatidyl-L-serine. Proteins 
were precipitated by the adition of 125 µL of cold 20% poly(ethylene glycol) 6000 and after 15-
minute incubation on a plate shaker at room temperature the filters were washed six times using a 
vacuum manifold with buffer containing 20 mM Tris-HCl (pH 7.5), 100 µM CaCl2 and 5 mM 
MgCl2. The plates were dried and 25 µL of Optiphase SuperMix liquid scintillant (PerkinElmer, 
Groningen, Netherlands) was added to each well. After equilibration period of at least two hours, 
radioactivity was measured using Wallac Microbeta Trilux microplate liquid scintillation counter 
(PerkinElmer, Waltham, MA, USA). All compounds tested were diluted in DMSO to give the 
same final DMSO concentration in the binding assay (4%) in each well. Since preliminary studies 
showed that the nonspecific binding was always less than 5%, only the total binding was 
measured, and all results were calculated as a percentage of control (DMSO) from the same plate. 
DMSO itself decreased [3H]PDBu binding to PKC  by 20% and to PKC  by 10%. 
 
[3H]PDBu Binding Assay for Determination of Binding Affinity Constants 
To determine Ki values for selected ligands, we used the method developed by the Blumberg 
group.47 Briefly, 20 ng/tube of purified human recombinant PKC  or  was incubated with 
different concentrations of the ligands for 10 minutes at 37 °C in a reaction mixture consisting of 
50 mM Tris-HCl (pH 7.4); 0.1 mg/mL phosphatidyl-L-serine; 1.8 mg/mL bovine IgG; [3H]PDBu 
and 0.1 mM calcium chloride (for PKC ) or 1 mM EGTA (for PKC ). Samples were chilled on 
ice for 10 minutes and 200 µL of 35% poly(ethylene glycol) 6000 in 50 mM Tris-HCl (pH 7.4) 
was added. The samples were mixed, incubated on ice for 15 minutes and centrifuged at 4 °C 
(15000g, 15 min). Radioactivity was determined from 100 µL aliquots of supernatants and from 
dried pellets by scintillation counting after addition of Optiphase HiSafe 3 liquid scintillant and 16-
hour equilibration. The results were calculated according to Lewin and Blumberg.47 The 
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dissociation constants (Kd) for the individual PKC isoenzymes and inhibitory dissociation 
constants (Ki) for the compounds were calculated with GraphPad Prism4 software (GraphPad 
Software Inc., La Jolla, CA, USA). 
 
Determination of ERK Phosphorylation by Immunoblotting 
To study the effects of the compounds on ERK1/2 phosphorylation, HeLa cells were treated with 
the test compounds in the presence or absence of PMA or inhibitors. The amount of 
phosphorylated ERK1/2 was determined by western blotting. The cells were seeded onto 6-well 
plates at a density of 4.0 × 105 cells / well. Twenty to twenty-four hours after seeding the medium 
was changed to serum-free DMEM. After a 24-hour serum starvation incubation, the cells were 
treated with the test compounds for the indicated times, washed twice with ice-cold PBS and then 
harvested in ice cold lysis buffer containing 20 mM Tris-HCl (pH 7.4), 0.1% Triton X-100, 2 mM 
EDTA, 10 mM EGTA, 2 mM Na3VO4 and protease and phosphatase inhibitors according to 
manufacturer’s instructions (see Materials and general procedures). After a 30-minute incubation 
on ice the cell lysates were centrifuged at 16000g for 15 minutes at 4 °C and the protein 
concentrations of the supernatants were determined using Bradford’s method. The samples were 
diluted in Laemmli sample buffer at equal concentrations and stored at -20 °C. Twenty micrograms 
of protein per lane were subjected to SDS-PAGE and then transferred to nitrocellulose membranes. 
Membranes were washed for 5 minutes with 0.1% Tween 20 in Tris-buffered saline (TTBS) and 
then blocked for 1 hour with 5% non-fat milk powder in TTBS (milk-TTBS). The membranes 
were then cut just above the 37 kDa marker band and incubated with the primary antibody (Anti-
ACTIVE® MAPK pAb 1:5000 or anti-GAPDH mAb 1:10 000 in milk-TTBS) overnight at 4 °C. 
Membranes were then washed for total of 35 min with TTBS and incubated with horseradish 
peroxidase-conjugated secondary antibody (goat anti-rabbit IgG or goat anti-mouse IgG 1:3000 in 
milk-TTBS) for one hour at room temperature. After washing (total of 40 minutes with TTBS), the 
bands were visualized with ECL. GAPDH bands were used as controls to ensure equal loading of 
proteins to all wells in the SDS-PAGE gel. Western blots were quantified by measuring the optical 
density of the immunoreactive bands with Scion Image software (http://scioncorp.com).  
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Table 1. 5-(Hydroxymethyl)isophthalates 1a1-3 and 1b1-21, their clogP values and 
binding affinity to PKC  and . The binding affinity was screened as described in the 
experimental section and is expressed as mean ± sem (n = 3-8) of residual [3H]PDBu 





























PKCδ (% of 
control)
1a1 8.35 58.0 ± 2.9 47.2 ± 5.6 1b10 5.89 45.0 ± 2.7 30.7 ± 1.7
1a2 6.12 54.7 ± 3.2 44.0 ± 3.6 1b11 6.95 33.2 ± 1.7 23.1 ± 3.3
1a3 6.46 56.5 ± 2.9 46.9 ± 2.6 1b12 5.89 56.0 ± 3.5 41.1 ± 2.9
1b1 6.33 59.4 ± 3.7 43.4 ± 1.6 1b13 6.95 39.3 ± 3.0 28.3 ± 3.2
1b2 6.07 59.9 ± 4.6 45.7 ± 2.8 1b14 7.97 73.3 ± 3.7 58.8 ± 0.4
1b3 6.07 53.3 ± 0.9 42.0 ± 2.0 1b15 7.97 67.4 ± 3.9 49.6 ± 1.4
1b4 6.07 56.1 ± 2.9 43.3 ± 2.0 1b16 5.53 65.7 ± 3.3 44.2 ± 0.6
1b5 6.07 49.6 ± 3.3 41.2 ± 4.1 1b17 1.30 116.7 ± 4.6 128.2 ± 5.3
1b6 6.07 52.7 ± 7.3 44.6 ± 1.3 1b18 0.69 114.2 ± 7.4
126.1 ± 
10.9
1b7 8.19 64.4 ± 4.0 49.5 ± 5.4 1b19 2.35 90.0 ± 4.9 89.6 ± 3.1
1b8 6.89 59.5 ± 5.0 38.0 ± 2.0 1b20 0.82 97.9 ± 1.4 91.4 ± 4.3
1b9 6.34 68.0 ± 2.9 52.5 ± 0.9 1b21 2.10 92.4 ± 2.0 87.1 ± 4.6
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Table 2. Synthesized derivatives, their clogP values and binding affinity to PKC  and . 
The binding affinity was screened as described in the experimental section and is 
expressed as the mean ± sem (n = 3-8) of residual [3H]PDBu binding (% of control) with 























PKCδ (% of 
control)
15a 7.11 93.7 ± 5.9 104.9 ± 9.4 27 4.43 93.2 ± 4.1 83.8 ± 7.0
15b 7.61 96.7 ± 3.6 90.0 ± 1.9 30 6.05 102.7 ± 7.2
100.6 ± 
10.2
15c 4.6 92.4 ± 4.3 78.1 ± 6.7 36a 4.84 66.3 ± 7.1 73.9 ± 4.2
15d 6.85 101.3 ± 3.9 98.8 ± 5.4 36b 4.26 83.0 ± 10.3 102.6 ± 7.1
15e 7.25 97.6 ± 5.2 97.7 ± 16.6 36c 3.21 96.5 ± 9.2 114 ± 7.1
22a 3.72 91.2 ± 3.3 88.4 ± 3.0 36d 1.80 103.6 ± 4.7 102.3 ± 9.6
22b 4.12 98.1 ± 4.5 94.0 ± 5.2 36e 0.56 102.9 ± 5.3 118.3 ± 9.8
22c 4.03 100.3 ± 8.3 110.1 ± 6.7 39 3.01 91.6 ± 9.2 95.3 ± 6.8
24a 4.70 80.6 ± 1.4 84.7 ± 6.1
24b 4.29 90.4 ± 5.9 83.0 ± 7.8
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Table 3. Binding affinities of selected isophthalate derivatives. Data represent the means 
± sem. The number of independent experiments is shown in parentheses (n.d. = not 
determined) 
  Ki (nM) Ki (nM) 
  PKC α PKC δ 
1a3 205 ± 14 (4) 590 ± 195 (4) 
1b10 661 ± 90 (3) 915 ± 132 (3) 
1b11 319 ± 12 (3) 529 ± 61 (3) 
DOG 40.1 ± 6.0 (4) n.d. 
Bryostatin 1 n.d. 0.44 ± 0.08 (5) 
 
 
Scheme 1 a. 
aConditions: (a) DHP, PPTS, DCE, rt, 6 h, 97%; (b) KOH (10%, aq.), MeOH, reflux, 1 
h, 85%; (c) alkyl halide, K2CO3, KI, DMF, 110 °C, 2 h (5a1-3) or alcohol, CDI, DMAP, 
DBU, DMF, rt → 40 °C, 22 h (5b1-19); (d) Dowex 50W×8, MeOH, 40 °C, overnight, 
10-95% (two steps). 
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Scheme 2 a. 
 
aConditions: (a) 2-methyl-1-pentanol, CDI, DMAP, DBU, DMF, rt → 40 °C, 19-21 h 




Scheme 3 a. 
 
aConditions: (a) NaOH (1.05 equiv.), MeOH, acetone, rt, 21 h then NaOH (0.1 equiv.), 
rt, 4 h, 98%; (b) BH3∙SMe2, THF, 0 °C → rt, 5 h, 29%; (c) DHP, PPTS, DCE, rt, 16 h, 
99%; (d) KOH (10%, aq.), MeOH, 90 °C, 17 h, 67%; (e) alcohol, CDI, DMAP, DBU, 
DMF, rt → 40 °C, 21 h; (f) Dowex 50W×8, MeOH, 40 °C, 17 h, 65-75% (two steps). 
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Scheme 4 a. 
aConditions: (a) DIPEA, EDC, HOBt, amine, rt → 40 °C, 4-23 h; (b) Dowex 50W×8, 
MeOH, 40 °C, 23-24 h, 28-39% (two steps). 
 
 
Scheme 5 a. 
 
aConditions: (a) Heptanoyl chloride (R = (CH2)5CH3), pyridine, DCM, rt, 20 h; (b) 
KOH (10%, aq.), MeOH, rt, 4 h, 95%; (c) H2, Pd/ C (10%), EtOH:EtOAc (2:1), rt, 22 h, 
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Scheme 6 a. 
aConditions: (a) BH3∙SMe2, THF, 0 °C → 60 °C, 21 h, 86%; (b) DHP, PPTS, DCE, rt, 
25 h, 99%; (c) H2, Pd/ C (10%), EtOH:THF (2:1), rt, 23 h, 100%; (d) RCO2H, DIPEA, 
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Scheme 7 a. 
aConditions: (a) KOH (1 equiv.), MeOH, 40 °C, 20 h, 65%; (b) DIPEA, EDC, HOBt, 
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Figure 1. The crystal structure of PKC  C1b domain complexed with phorbol-13-O-
acetate.31 The pivotal polar functional groups of the phorbol ester involved in C1 domain 
recognition include the hydroxyl groups attached to carbon C4 and C20 and the carbonyl 
group on C3. The carbonyls of Gly 253 and Leu 251 are HBAs (green arrows) and the 
amide proton of Gly 253 and Thr 242 are HBDs (red arrows). The figure was created 
using VMD (v.1.8.6., University of Illinois, USA). 
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Figure 2. Dipentyl (5-hydroxymethyl)isophthalate (I) docked in the PKC  C1b domain. 
The hydroxyl group of the ligand is hydrogen bonded to the backbone amide proton of 
Thr 242 (red arrow) and the carbonyls of Thr 242 and Leu 251 (green arrows). The model 
also shows that one of the carbonyl groups of the template (I) forms a hydrogen bond 
with the backbone amide proton of Gly 253 (red arrow). A bridging water molecule 
between the backbone carbonyl of Met 239 and the other carbonyl (black arrows) could 
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Figure 3. Binding of selected isophthalate derivatives to purified PKC  and . Binding 
of 10 nM [3H]PDBu was measured in the presence of different concentrations of the 
isophthalate derivatives. Representative competition binding curves for A) PKC  and 
1a3, B) PKC  and 1b10, C) PKC  and 1b11, D) PKC  and 1a3, E) PKC  and 1b10 
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Figure 4. The effects of 1a3, 1b10 and 1b11 on ERK1/2 phosphorylation in HeLa cells. 
A) Cells were treated with 20 µM concentration of 1a3, 1b10 or 1b11 for the indicated 
times. The PKC inhibitor Gö6983 (1 µM) or the MEK inhibitor U0126 (10 µM) were 
added to the cells 5 minutes before the addition of the test compounds. PMA (10 nM for 
5 minutes) was used as a positive control. Cells were harvested and ERK1/2 
phosphorylation was detected as described in Experimental section. B) The effect of 
1b11 on PMA-induced ERK1/2 phosphorylation. A representative blot from a single 
experiment (upper panel) and quantification results (mean ± sem) from three independent 
experiments are shown (lower panel). The cells were treated with different concentrations 
of 1b11 for 25 minutes and subsequently stimulated with 10 nM of PMA for 5 minutes. 
The cells were then harvested and ERK1/2 phosphorylation was detected as described in 
the Experimental section. a) Untreated cells, b) PMA alone, c) 1 µM of 1b11 + PMA, d) 
5 µM of 1b11 + PMA, e) 20 µM of 1b11 + PMA, f) 20 µM of 1b11 alone. 
 
 
